Esophagus News

Patients with systemic sclerosis who report more severe reflux symptoms demonstrate worse interstitial lung disease outcomes despite receiving standard therapy, according to data published in Arthritis Care & Research.

Although individuals in China with low-grade intraepithelial neoplasia are at higher risk for developing esophageal squamous cell carcinoma, that risk can be reduced by more than 30% with surveillance endoscopy, according to research.

Weekly subcutaneous doses of dupilumab improved histologic outcomes and alleviated symptoms for adults and adolescents with eosinophilic esophagitis, according to a study published in The New England Journal of Medicine.

Follow-up esophagogastric junction sampling for intestinal metaplasia may not be necessary in patients after complete and successful eradication therapy for Barrett’s esophagus, researchers reported.

The prevalence of eosinophilic esophagitis may be several times higher among patients with atopic disease than among the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

CHARLOTTE, N.C. — Among patients who underwent lung transplantation, laparoscopic Toupet fundoplication provided objective acid reflux control and preserved lung function and foregut motility, according to late-breaking data.

Gastroesophageal reflux disease affects 1 in 5 people in the United States.; although common, the disease is often unrecognized and misunderstood, the International Foundation for Gastrointestinal Disorders reported.

CHARLOTTE, N.C. — Achalasia was associated with an increased risk for esophageal cancer among a cohort of veterans, suggesting the need for increased endoscopic surveillance, according to a presenter at the ACG Annual Scientific Meeting.

The FDA has granted breakthrough device designation to EndoStim for its implantable device which serves as a treatment option for patients with refractory gastroesophageal reflux disease, according to a manufacturer release.

CHARLOTTE, N.C. — Dupilumab maintains its safety and efficacy for up to 52 weeks in patients with eosinophilic esophagitis, according to late-breaking data from the phase 3 LIBERTY EoE TREET study presented at ACG Annual Scientific Meeting.